Table 1.

Clinical Characteristics of Patients With 30-Day Mortality

Case	Age, Sex	Pathogen	Culture Specimen	Infection Source	ERV Start, h	ERV Duration, d	APACHE II	SOFA Score	ICU Stay, d	Prior Active Antimicrobial Therapy	Combination Antimicrobial Therapy With ERV	Days to Mortality	30-Day Recurrence	Reason for ERV Selection
1	48 F	Proteus mirabilis Enterococcus faecium	Blooda	Urinary	8	3	21	4	20	AMK, CZA, IPM, MEM, C/T	CZA	5	No	Consolidation of therapy regimen
2	53 M	Escherichia coli	Fluid	Intra-abdominal	NAb	26.5	11	4	26	None	None	26	No	Double coverage for suspected CREe
3	54 M	Stenotrophomonas maltophilia	Blooda	Respiratory	2.5	13.5	23	8	45	None	None	16	No	Pathogen resistant to LVX and SXT
4	61 M	Enterococcus faecium Klebsiella pneumoniae	Fluid	Intra-abdominal	NAb	9.5	24	14	63	MEM, TZP	None	22	No	Concern for polymicrobial infection
5	77 F	Acinetobacter baumannii Enterobacter cloacae Escherichia coli	Tissue	Skin/soft tissue	19	15.5	15	1	1	TGC	None	15	No	Preference to TGC due to adverse event profile
6	65 M	Acinetobacter baumannii	BAL	Respiratory	20	12	26	4	20	AMK, CZA, IPM, MEM, C/T, CZA	CZA	13	No	Recurrent infection with previous regimens of TGC and TOB
7	69 M	Enterococcus faecium Bacteroides fragilis	Blooda Fluidc	Intra-abdominal	7	28	15	2	22	None	DAP LZD	28	Yesd	Persistent VRE bloodstream infection
8	59 F	None: empiric coverage per patient history	None f	Respiratory	NAg	3	21	3	4	None	MEM, VAN	26	No	Drug rash to CZA and double coverage for suspected CRE
9	62 M	Escherichia coli Klebsiella aerogenes Enterococcus faecalis	Blooda	Intra-abdominal	1.5	3	28	4	5	MEM, TZP, VAN	MEM, MTZ	20	No	Consolidation of therapy regimen

Abbreviations: AMK, amikacin; BAL, bronchoalveolar lavage; CRE, carbapenem-resistant Enterobacteriaceae; C/T, ceftolozane-tazobactam; CAZ, ceftazidime; CZA, ceftazidime/avibactam; DAP, daptomycin; ERV, eravacycline; F, female; FEP, cefepime; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; M, male; MEM, meropenem; MTZ, metronidazole; NA, not applicable; PMB, polymyxin B; SXT, trimethoprim-sulfamethoxazole; TOB, tobramycin; TGC, tigecycline; TZP, piperacillin-tazobactam; VAN, vancomycin; VRE, vancomycin-resistant enterococci.

^aAll cases have cleared their blood cultures. Cases 1 and 7 used ERV after blood culture clearance, whereas cases 3 and 9 used ERV before blood culture clearance.

^bTime to ERV administration from positive culture was not possible to calculate because patient was a transfer with no documentation of timing of first culture in cases 2 and 3, while in case 8 no culture was isolated from the patient (empiric therapy).

^c Enterococcus faecium growing from blood and Bacteroides fragilis from fluid.

^dThe subject’s symptoms resolved initially, but the subject had a 30-day recurrence, followed by 30-day mortality.

^ePatient was administered eravacycline for the purpose of double coverage at another institution before referral to the current institution. In the current study institution, no double coverage or combination agent was administered.

^fNo organisms were isolated because the regimen was empiric.

^gTime to ERV administration from positive culture was not possible to calculate because therapy was empiric with no culture.